Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC

Traders Union
All News
Companies
Summit Therapeutics drops 3.94% today

Highlights

SMTT shows short-term bullish momentum, trading above near-term averages but remains in an overall downtrend below long-term resistance.
Short-term volatility is high at 18.75%, with price consolidation signaling a neutral to cautious outlook heading into next week.
Expected trading range is $17.09–$17.20, with limited upside potential and near-term risk skewed toward a downside move if support breaks.

SMMT is currently trading at $16.58, sitting above both the MA-20 ($15.91) and MA-50 ($15.76), suggesting supportive short- and medium-term momentum. However, it remains well below the longer-term MA-200 ($19.86), indicating persistent downside pressure for the broader trend. The Ichimoku Kijun level stands at $16.42, now just below the spot price and acting as immediate support. Near-term support is clustered around MA-20/MA-50 ($15.91–$15.76), while $16.42 (Kijun) reinforces key support. The first layer of resistance is at the MA-100 ($16.79), with the MA-200 ($19.86) above as key resistance.

MACD on D1 signals a mild bullish shift, but ADX remains neutral at low strength, hinting at a trend lacking force. Momentum oscillators reveal mixed signals: RSI D1 is bullish (54.11), but CCI registers overbought territory, and Stoch RSI is neutral. BBP at 1.15 points to ongoing buyer dominance in intraday trading. Awesome Oscillator is supportive and signals moderate upward momentum. In today’s session, SMMT slid 3.94%, reflecting meaningful short-term volatility. Over the past week, SMMT is trading at $16.58, up from $15.51 a week ago, reflecting a 6.90% gain. The price is positioned in the middle of the weekly range. Weekly volatility stands at 18.75%. Price action shows a recovery from the weekly low but also signals consolidation below resistance.

For the coming week, the expected trading range is forecast between $17.09 and $17.20, with SMMT tracking toward the lower midrange of its 52-week span ($13.83–$36.91). The probability of a price increase is very low (less than 20%), making further declines the more likely near-term outcome. The baseline scenario anticipates sideways movement as the price stabilizes between recent support and resistance. In a bullish case, a close above $16.79 (MA-100) could trigger a push toward $17.20 and higher. Conversely, a bearish break below $16.42 (Kijun) and $15.91 (MA-20) may open a decline toward $15.76 or even lower if weekly volatility persists.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.